Amicus Therapeutics Prices Underwritten Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Amicus Therapeutics (FOLD) Prices 16.98M Common Secondary Offering at $13.25/Share
June 12, 2015 6:17 AM EDTAmicus Therapeutics (NASDAQ: FOLD) announced the pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses... More
